COA
Certificate of Analysis
Third-party HPLC and MS testing for every batch, published before purchase and tied to the batch being sold.
HPLC / MS
Endocrine Research
CJC-1295 No DAC5mg
GHRH analog for GH-axis research without DAC modification.
$65per vial
Product handling note
Lyophilized powder may shift or come loose during transit; that is a normal occurrence and does not affect the integrity of the research product. Fill appearance and batch-specific details may vary. Refer to the Certificate of Analysis below for the documentation tied to the current batch.
Research overview
Why researchers study CJC-1295 No DAC.
CJC-1295 No DAC is studied as a GHRH analog research material without the drug affinity complex modification. The useful research frame is GH-axis signaling, pulse behavior, and how a single GHRH analog compares against paired or longer-acting lanes.
Listing it separately keeps the component story clean. Researchers can compare CJC-1295 No DAC against CJC-1295 + Ipamorelin, Ipamorelin alone, and Tesamorelin without mixing single-compound and blend contexts.
The receipts
What you get with every vial.
ID
Batch traceability
Every vial is stamped with a batch ID that links back to its COA, source record, and current product documentation.
Batch linkedLabel
Batch-linked labeling
Product identity, strength, and batch reference stay easy to match from the product listing to the vial in hand.
Listing to vialRelated peptides
Adjacent research lanes.
Endocrine
CJC-1295 + Ipamorelin10mg
GHRH analog plus ghrelin-receptor secretagogue blend for GH-axis research.
$75View product→
Endocrine
Ipamorelin10mg
Selective ghrelin-receptor secretagogue for GH-axis research.
$65View product→
Endocrine
Tesamorelin10mg
Growth hormone-releasing hormone analog for endocrine-axis research.
$80View product→
Product FAQ
Common research questions.
What does No DAC mean?
No DAC means the material is presented without the drug affinity complex modification associated with longer-acting CJC-1295 research. The product page keeps that distinction explicit so the batch story is not ambiguous.
Why study single-component CJC-1295 separately?
A single-component listing gives researchers a cleaner GHRH analog comparison point. It avoids blending the CJC lane with a separate secretagogue lane such as Ipamorelin.
How is this different from CJC-1295 + Ipamorelin?
CJC-1295 No DAC is the GHRH analog lane by itself. CJC-1295 + Ipamorelin combines that lane with an Ipamorelin secretagogue context, so the batch record and research framing are different.
What should the batch documentation clarify?
It should clarify identity, purity, labeled strength, measured strength where available, batch code, and that the vial is the No DAC CJC-1295 material.
Research sources
Literature links are included for background reading. Batch-specific identity and purity details live in the COA tied to the current batch.